Seventure Partners

Aenitis Technologies is a French start-up founded in July 2014 by researchers Mauricio Hoyos and Jean-Luc Aider from the CNRS. The company specializes in the development of innovative medical devices that address challenges in cell therapy preparation and bioprocessing. Aenitis Technologies focuses on solutions for cell sorting, washing, and isolation, utilizing acoustophoresis technologies to enhance the efficiency of these processes. With an emphasis on revolutionizing practices in public health, Aenitis Technologies aims to establish itself as a world leader in the separation and filtration of biological elements, providing vital support to cell therapy units and blood banks in the healthcare industry.

Nexess SAS is a French company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Established in 2006 and headquartered in Mougins, France, with an additional office in Paris, Nexess offers a comprehensive range of products, including the NexLink software platform, which enhances security and productivity. The company also provides a variety of identification products such as personal security badges, RFID tags, and mobile devices, as well as smart camera systems that enable autonomous image analysis and real-time data transmission. Its solutions are designed for applications like hazardous product traceability, secure equipment management, site localization, and access detection in hazardous zones. Nexess aims to support digital transformation projects through its innovative technology, enhancing productivity, quality, and security for its clients.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Hardloop is an online retailer based in Paris, France, specializing in sports products and adventure gear. Established in 2014, the company offers a diverse range of equipment and clothing for various outdoor activities, including hiking, trail running, skiing, climbing, and swimming. Through its platform, Hardloop provides sports enthusiasts with access to a wide selection of shoes, gloves, bottles, and other essential accessories from numerous international brands, catering to the needs of those seeking new adventures in sports.

Expensya SAS is a Paris-based company specializing in multi-platform expense management software solutions. Founded in 2015, the company provides a web and mobile application designed to automate the entire process of expense report management, from receipt handling to archiving. The platform incorporates advanced technologies, including Cloud computing, Artificial Intelligence, and Machine Learning, to enhance efficiency and streamline workflows. Expensya's application is compatible with various devices, including Android, iOS, and Windows phones, and supports eight languages while adapting to local accounting regulations in approximately fifty countries. Its features include expense management, data export, accountant integration, approval workflows, and a statistics module, making it a comprehensive tool for businesses seeking to simplify and secure their expense reporting processes.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Hardloop is an online retailer based in Paris, France, specializing in sports products and adventure gear. Established in 2014, the company offers a diverse range of equipment and clothing for various outdoor activities, including hiking, trail running, skiing, climbing, and swimming. Through its platform, Hardloop provides sports enthusiasts with access to a wide selection of shoes, gloves, bottles, and other essential accessories from numerous international brands, catering to the needs of those seeking new adventures in sports.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

Expensya SAS is a Paris-based company specializing in multi-platform expense management software solutions. Founded in 2015, the company provides a web and mobile application designed to automate the entire process of expense report management, from receipt handling to archiving. The platform incorporates advanced technologies, including Cloud computing, Artificial Intelligence, and Machine Learning, to enhance efficiency and streamline workflows. Expensya's application is compatible with various devices, including Android, iOS, and Windows phones, and supports eight languages while adapting to local accounting regulations in approximately fifty countries. Its features include expense management, data export, accountant integration, approval workflows, and a statistics module, making it a comprehensive tool for businesses seeking to simplify and secure their expense reporting processes.

Launchmetrics is a marketing and analytics platform that specializes in serving the fashion, luxury, and beauty industries. Founded in 2006 and headquartered in New York, with additional operations in Paris, the company offers a suite of products designed to enhance brand performance and streamline marketing processes. Its offerings include Samples, Events, Contacts, Discover, and Influencers by Launchmetrics, which collectively assist brands in planning product launches and improving media performance. The company has established itself as a trusted technology provider, working with over 1,000 clients, including prominent names like Dior, Fendi, and NET-A-PORTER, as well as partners such as the British Fashion Council and Google. With a presence in eight markets and support in five languages, Launchmetrics aims to empower brands to create impactful and measurable consumer experiences, adapting to the rapidly changing digital landscape. The company was originally known as Fashion GPS, Inc. before rebranding in January 2016.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Intento Design SA, founded in 2015 and based in Paris, France, specializes in developing software that enhances the efficiency of analog and mixed-signal integrated circuit development. The company's flagship product, ID-Xplore, automates the analog design process from hand analysis to simulation, significantly reducing the time required for circuit sizing. Intento Design also provides services such as methodology adoption, design collaboration, and technology migration. Their solutions are tailored for designers in various markets, including consumer electronics, Internet of Things, big data, military, and medical sectors. The company's innovative approach originated from research conducted at Laboratoire d’Informatique de Paris 6, resulting in a robust portfolio of intellectual property focused on accelerating the design cycle for complex systems-on-chips (SoCs).

Botfuel, established in 2016 and headquartered in Paris, France, specializes in a web-based platform and SDK for creating and deploying chatbots. It empowers individuals and businesses to engage with customers on popular messaging channels, providing automated, personalized support and enhancing brand engagement. The platform leverages AI to develop modular, scalable chatbots, aiming to improve customer support and drive sales.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

MilliDrop Instruments SAS is a Paris-based company that specializes in the design and development of advanced cell culture machines utilizing millifluidics technology for bacteriological research and diagnostics. Established in 2015, MilliDrop focuses on creating innovative in vitro diagnostics instruments, such as the MilliDrop DIV, which facilitate the identification of infectious agents and the determination of appropriate antibiotic dosages. These instruments allow for the incubation, analysis, and manipulation of microscopic samples ranging from approximately 100 nanoliters to a few picoliters in volume. By enabling microbiologists to simultaneously study various cultures, monitor phenotypic diversity, and conduct serial dilutions, MilliDrop enhances the efficiency and accuracy of antimicrobial susceptibility testing across a range of microorganisms, including bacteria, fungi, and yeasts.

Intento Design SA, founded in 2015 and based in Paris, France, specializes in developing software that enhances the efficiency of analog and mixed-signal integrated circuit development. The company's flagship product, ID-Xplore, automates the analog design process from hand analysis to simulation, significantly reducing the time required for circuit sizing. Intento Design also provides services such as methodology adoption, design collaboration, and technology migration. Their solutions are tailored for designers in various markets, including consumer electronics, Internet of Things, big data, military, and medical sectors. The company's innovative approach originated from research conducted at Laboratoire d’Informatique de Paris 6, resulting in a robust portfolio of intellectual property focused on accelerating the design cycle for complex systems-on-chips (SoCs).

Eligo Bioscience S.A.S is a biotechnology company founded in 2014 and based in Paris, France, specializing in the development of Eligobiotics, a novel class of antimicrobials. These therapeutics are designed to target specific bacteria based on their genomic information, utilizing a combination of CRISPR/Cas technology and engineered phage capsids. This advanced approach allows Eligo to create precision antibiotics aimed at eradicating resistant pathogens and virulent bacteria within the human microbiome. The applications of Eligobiotics extend beyond pharmaceuticals; they also encompass areas such as cosmetics and biodefense, addressing a variety of bacteria-associated diseases and offering next-generation solutions to combat superbugs.

Aenitis Technologies is a French start-up founded in July 2014 by researchers Mauricio Hoyos and Jean-Luc Aider from the CNRS. The company specializes in the development of innovative medical devices that address challenges in cell therapy preparation and bioprocessing. Aenitis Technologies focuses on solutions for cell sorting, washing, and isolation, utilizing acoustophoresis technologies to enhance the efficiency of these processes. With an emphasis on revolutionizing practices in public health, Aenitis Technologies aims to establish itself as a world leader in the separation and filtration of biological elements, providing vital support to cell therapy units and blood banks in the healthcare industry.

Open Ocean SAS is a French company, established in 2011 and operating out of Brest and Paris, that specializes in developing SaaS-based decision-making platforms for offshore infrastructure and marine operations. The company offers a range of innovative solutions, including the Metocean Analytics tool, which analyzes atmospheric and oceanic conditions, and provides comprehensive reports on tidal energy markets in France. Additionally, Open Ocean produces a spectral wave database to support the development of marine renewable energy in Scotland. Their services include site data analysis, resource and energy assessment, environmental impact assessments, and adherence to greenhouse gas protocols for wave and tidal energy projects. Open Ocean's highly qualified team of oceanographers, trained at leading research institutions, focuses on high-resolution modeling, statistical analysis, and data mining, catering to farm developers, operators, and public agencies in the renewable marine energy sector. As of September 2019, Open Ocean operates as a subsidiary of Artelia SAS.

JobTeaser SARL operates a recruitment platform designed specifically for students and recent graduates. Founded in 2008 and based in Paris, France, the company facilitates the search for internships and entry-level jobs through its online platform, which offers tailored opportunities based on user profiles. JobTeaser is integrated into over 750 educational institutions, providing access to 5 million users and enabling more than 250,000 recruiters to connect with emerging talent. The platform not only assists with job placements but also offers career guidance, videos to explore various career paths, and advice on making informed career choices. Additionally, it includes features that allow direct communication between job seekers and recruiters, enhancing the overall job search experience.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Nexess SAS is a French company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Established in 2006 and headquartered in Mougins, France, with an additional office in Paris, Nexess offers a comprehensive range of products, including the NexLink software platform, which enhances security and productivity. The company also provides a variety of identification products such as personal security badges, RFID tags, and mobile devices, as well as smart camera systems that enable autonomous image analysis and real-time data transmission. Its solutions are designed for applications like hazardous product traceability, secure equipment management, site localization, and access detection in hazardous zones. Nexess aims to support digital transformation projects through its innovative technology, enhancing productivity, quality, and security for its clients.

Biophytis SA is a clinical-stage biotechnology company headquartered in Paris, France, dedicated to developing therapeutics aimed at slowing the degenerative processes associated with aging and enhancing functional outcomes for patients with age-related diseases. The company is focused on activating key biological resilience pathways that may protect against the effects of various biological and environmental stresses linked to these diseases. Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule designed for treating neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy. Additionally, its second candidate, Macuneos (BIO201), targets retinal diseases, including age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon to further the development of Sarconeos. Since its founding in 2006, Biophytis has aimed to position itself as a leader in the emerging field of aging science by providing innovative therapies for patients with limited treatment options.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Impeto Medical SAS is a privately owned medical device company established in June 2005, with its headquarters located in Paris, France, and additional subsidiaries in China and San Diego, California. The company specializes in the manufacture and marketing of non-invasive diagnostic devices that assess eccrine sweat gland activity. Its product lineup includes SUDOSCAN+, which is used for detecting and monitoring peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardio metabolic risks; and SUDOSCAN, a device that evaluates galvanic skin response to assess sympathetic nervous system behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical's innovative technology enables healthcare professionals to screen large patient populations effectively, facilitating early detection of metabolic disorders and related complications. The company distributes its products through a network of distributors.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, Enterome specializes in the development of disease management solutions leveraging the gut microbiome. It focuses on creating biomarkers and therapeutics for microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company utilizes its proprietary OncoMimic technology to address cancer treatment by overcoming immune tolerance against tumors, enabling the development of off-the-shelf therapies that prompt a robust immune response. Enterome's innovative drug candidates, which include small proteins and peptides, aim to generate an endogenous CD8 T cell response and are currently advancing through Phase 2 clinical trials for challenging cancers such as glioblastoma and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development capabilities.

Arlettie, founded in 1993 and based in Paris, France, specializes in online retail of fashion apparel and accessories. The company operates as an intermediary between luxury and fashion brands and consumers, organizing private sales and exclusive shopping events. Through its platform, Arlettie offers a curated selection of luxury fashion, accessories, and lifestyle products from renowned brands, facilitating unique shopping experiences for discerning customers.

Efficity SAS is an online real estate agency located in Paris, France, established in 2007. The company specializes in providing a range of online real estate services, including the buying and selling of properties, property management, and property valuation. Efficity leverages digital platforms to facilitate real estate transactions, enabling clients to navigate the property market efficiently.

Glowria offers online digital video disc (DVD) rental service. Glowria was founded in 2003 is based in Paris, France.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software, primarily catering to Fortune 500 companies. With additional offices in the UK and the US, the company employs over 80 staff members worldwide. Sefas' flagship product, the Open Print software suite, is utilized by various sectors, including financial services, banking, insurance, utilities, telecommunications, and the public sector, for designing, composing, and producing complex business-to-consumer documents. Its unique capability to integrate data from multiple sources allows for the creation of personalized communications. Recently, Open Print has been increasingly adopted for redesigning mission-critical documents to incorporate marketing campaigns, thereby generating new revenue opportunities. The UK office, established in 1999 in Bristol, serves notable clients such as Nationwide and British Telecom, who have been utilizing Sefas' solutions since the early 2000s.

DSO Interactive SA designs, develops, and markets software solutions for intermediation of Internet platforms. Its products include auditing and decisional software systems for legal firms. The company also offers information technology and communication consulting services. It was formerly known as Convergence SA and changed its name to DSO Interactive in September 2004. The company was founded in 2001 and is based in Paris, France.